Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitisLisa A. Beck, Ainara Rodríguez Marco, Antonella Muraro et al.|Journal of Allergy and Clinical Immunology|2024Cited by 25
63281 Real-World Comorbidities of Adult Patients With Prurigo Nodularis Initiating Dupilumab in the USNicholas Mollanazar, Kwinten Bosman, Danielle L. Isaman et al.|Journal of the American Academy of Dermatology|2025Cited by 1
63345 Real-World Comorbidities of Adult Patients With Prurigo Nodularis Initiating Dupilumab in the US by Race/EthnicityShawn G. Kwatra, Kwinten Bosman, Simmi Wiggins et al.|Journal of the American Academy of Dermatology|2025Cited by 0
63337 Real-World Prevalence of Comorbidities Among Adult Patients With Prurigo Nodularis With and Without Type 2 Inflammatory Diseases in the USBrian Kim, Kwinten Bosman, Danielle L. Isaman et al.|Journal of the American Academy of Dermatology|2025Cited by 0
63341 Real-World Comorbidities, Treatment Use, and Healthcare Resource Utilization Among Elderly Patients With Prurigo Nodularis Initiating Dupilumab in the USGil Yosipovitch, Kwinten Bosman, Danielle L. Isaman et al.|Journal of the American Academy of Dermatology|2025Cited by 0